Metformin for Longevity: What the Research Shows | telos rx
Hiker with a backpack walking a rocky forest trail, representing active healthy aging and metformin for longevity research
← Back to blog
healthy aging

Metformin for Longevity: What the Research Shows

By TelosRX Editorial Team

Metformin for longevity shows promise in worms and some mice, but human evidence is mixed. No trial shows it extends healthy lifespan, and exercise studies raise real trade-offs. Explore measurable, provider-guided options with TelosRX.

Metformin is one of the most prescribed drugs on earth. It's cheap, generic and approved for type 2 diabetes. Somewhere along the way, it also became the poster child of the anti-aging world.

So does the evidence hold up? This review walks through the key studies one by one, from worms to monkeys to large human cohorts. You'll see what each found, where it falls short, and what the planned TAME trial is meant to settle.

Quick note before we start. Metformin is not FDA-approved for aging or longevity. Using it for that purpose is off-label and needs a licensed provider's judgment.

Why Metformin Became a Longevity Candidate

Metformin came from a plant. French lilac, also called goat's rue, contains compounds that lower blood sugar. Metformin is a refined, synthetic cousin of those compounds.

Researchers noticed two things over decades of use. First, people on metformin seemed to have fewer heart problems than expected. Second, the drug touches pathways that also show up in aging research.

That overlap made it an obvious test case. If a safe, cheap pill could slow aging, the impact would be enormous. That's a big "if."

How Metformin Is Thought to Work on Aging

Nobody fully agrees on metformin's main target. A detailed review lists several mechanisms researchers are studying (Trends in Endocrinology & Metabolism review, 2019):

  • Mitochondria: metformin mildly slows complex I, part of the cell's energy machinery.
  • AMPK: it activates this cellular energy sensor, which shifts cells toward maintenance.
  • mTORC1: it dampens this growth signal, the same pathway rapamycin targets.
  • Gut microbiome: it changes gut bacteria, which may explain some of its effects.
  • Inflammation: it may lower low-grade inflammation linked to aging.

The same review flags a catch. Many lab experiments use metformin levels 10 to 100 times higher than blood levels reached in people. Results in a dish may not carry over.

Finding 1: Worms Lived Longer on Metformin

The earliest longevity signals came from C. elegans, a tiny roundworm used in aging labs. Metformin extended lifespan and healthspan in several worm studies, as summarized in the same review.

Worms are useful because they live only a few weeks. That makes lifespan experiments fast and cheap.

The limit: worms aren't people. Many compounds that extend worm lifespan do nothing in mammals. This is a starting point, not proof.

Finding 2: A 2013 Mouse Study Showed a Modest Gain

The most-cited mammal result came in 2013. Male mice given metformin at 0.1% of their diet, starting in middle age, lived longer on average (Martin-Montalvo et al., Nature Communications 2013).

A later review puts the gain in mean lifespan at 5.8%. The mice also showed better physical performance and insulin sensitivity.

A higher dose of 1% of the diet was toxic and shortened lifespan. That's a useful reminder that more isn't better.

Finding 3: A Larger Mouse Program Found No Lifespan Gain

The National Institute on Aging runs the Interventions Testing Program, or ITP. It tests compounds at three sites at once, in genetically varied mice. That design makes results harder to fluke.

In the ITP, metformin alone at 0.1% of the diet "did not significantly extend lifespan" (Strong et al., Aging Cell 2016). Metformin combined with rapamycin did extend lifespan.

Why it matters: the more rigorous mouse test didn't confirm the 2013 result. For metformin on its own, the mammal data is split.

Finding 4: A UK Cohort Suggested a Survival Edge

In 2014, researchers studied UK health records. They compared 78,241 people with type 2 diabetes who started metformin against matched people without diabetes (Bannister et al., 2014).

People starting metformin had slightly longer survival than their matched controls without diabetes. People starting a sulfonylurea, another diabetes drug, had shorter survival.

This study launched a thousand headlines. It's also observational, meaning it can show a link but not cause and effect.

Finding 5: A Danish Reanalysis Did Not Confirm It

A 2022 study tried to replicate the UK finding using Danish national registries, including twins (Keys et al., International Journal of Epidemiology 2022).

It found the opposite pattern. People with type 2 diabetes on metformin had higher mortality than matched people without diabetes. The incidence rate ratio was 1.52 in singletons and 1.90 in twin pairs.

Adjusting for other health conditions shrank the gap. It still didn't produce a survival advantage. That result challenges the idea that metformin offers a built-in survival edge.

Interested in mitochondrial health? MOTS-c is a mitochondrial-derived peptide studied in metabolic research. Compounded MOTS-c is not FDA-approved. A licensed provider reviews your online intake asynchronously and decides whether it fits.

Learn about MOTS-c at TelosRX

Finding 6: Women Starting Metformin Were More Likely to Reach 90

A 2025 analysis used data from the Women's Health Initiative. It compared older women with new type 2 diabetes who started metformin versus a sulfonylurea (Journal of Gerontology, 2025).

Among 438 matched women, the adjusted risk of dying before age 90 was 30% lower with metformin. That's a striking number.

The catch: the comparison was against another diabetes drug, not against no drug. All participants had diabetes. It tells us little about healthy people taking metformin for longevity.

Finding 7: MILES Showed Gene Activity Changes

The Metformin in Longevity Study, or MILES, was small and carefully controlled. Fourteen adults around age 70 took metformin and placebo for six weeks each (Kulkarni et al., Aging Cell 2018).

Metformin changed the activity of 647 genes in muscle and 146 in fat tissue. Some were metabolic. Others involved DNA repair and collagen pathways.

Gene activity is a biomarker, not an outcome. It shows metformin does more than lower blood sugar. It doesn't show anyone lived longer or stayed healthier.

Finding 8: Metformin May Blunt Exercise Gains

This is where the story gets complicated. Two randomized trials in older adults tested metformin alongside exercise training.

  • Aerobic training: over 12 weeks, metformin weakened the expected gains in insulin sensitivity and VO2 max. It also blocked the rise in muscle mitochondrial respiration (Konopka et al., Aging Cell 2019).
  • Strength training: in the MASTERS trial, adults 65 and older took 1,700 mg daily or placebo during 14 weeks of training. The placebo group gained more lean mass and thigh muscle (Walton et al., Aging Cell 2019).

Exercise is one of the best-supported longevity habits we have. A drug that dulls its benefits is a real trade-off for healthy, active people.

Finding 9: Monkeys Showed Slower "Aging Clocks"

In 2024, a 40-month study gave metformin to adult male cynomolgus monkeys (Cell, 2024). Researchers built aging clocks from blood, tissue and DNA markers.

Metformin slowed several of these clocks. The authors reported about a six-year regression in estimated brain aging.

Primates are closer to us than mice. Still, aging clocks are estimates, not lifespan. The study included male monkeys only.

Evidence Summary: Metformin for Longevity at a Glance

Study Model Main finding Strength of evidence
Worm studies C. elegans Longer lifespan Low for humans
Martin-Montalvo 2013 Male mice Mean lifespan up 5.8% Moderate, single lab
ITP 2016 Varied mice, 3 sites No significant gain alone Higher rigor
Bannister 2014 UK records Slight survival edge vs non-diabetic controls Observational
Keys 2022 Danish registries No survival advantage Observational
WHI 2025 Older women with diabetes 30% lower risk of death before 90 vs sulfonylurea Observational
MILES 2018 14 older adults Gene activity changes Biomarker only
Konopka 2019 / MASTERS 2019 Older adults exercising Blunted exercise gains Randomized trials
Cell 2024 Male monkeys Slower aging clocks Biomarker only

Bottom line: the signals are real but inconsistent. The randomized human data we do have raises cautions rather than confirming benefits.

The TAME Trial: What It Plans to Test

TAME stands for Targeting Aging with Metformin. It's designed as a large, placebo-controlled trial in older adults.

According to published plans, it would enroll about 3,000 people aged 65 to 79. Participants would take 1,500 mg daily, with a mean follow-up over 3.5 years. The main endpoint is time to any of several age-related conditions, like heart disease, cancer or dementia.

TAME matters beyond metformin. It's meant to test whether "aging" itself can be a target for drug trials. As of the latest public reports, it has not reported results. Until it does, the fair answer to "does metformin slow aging?" is "we don't know yet."

Safety: What the Metformin Label Says

Metformin is generally well tolerated in people with diabetes. That doesn't make it risk-free for anyone. The FDA label highlights several points:

  • Stomach upset: nausea, diarrhea and gas are common, especially early on.
  • Vitamin B12: long-term use can lower B12 levels, so monitoring may be needed.
  • Lactic acidosis: a rare but serious boxed warning, with higher risk in kidney or liver disease.
  • Kidney function: it's not used in people with severely reduced kidney function.
  • Contrast imaging and surgery: it may need to be paused around these procedures.

The exercise trials add a longevity-specific concern. Metformin may reduce some fitness gains in healthy older adults.

How to Read Metformin Longevity Headlines

Metformin stories tend to travel faster than the data behind them. A few quick questions help you sort signal from noise.

  • Who was studied? Worms, mice, monkeys and people with diabetes are not healthy adults.
  • What was compared? "Better than a sulfonylurea" is not the same as "better than nothing."
  • What was measured? Gene activity and aging clocks are biomarkers, not years of life.
  • Was it randomized? Observational links can reflect who gets prescribed what, not the drug itself.
  • Was it replicated? The 2013 mouse result and the UK cohort both met mixed follow-ups.

Run any new headline through those five questions. Most "metformin slows aging" claims shrink quickly.

Questions to Ask a Provider About Metformin

If you're curious about metformin for longevity, bring specific questions to a licensed provider. A good conversation covers more than "is it safe?"

  1. Do my blood sugar or insulin markers suggest any metabolic reason to consider it?
  2. How are my kidney and liver numbers, and how often would we recheck them?
  3. Should we track vitamin B12 if I take it long term?
  4. How might it affect my training goals, given the exercise trial results?
  5. What would we measure to decide whether it's worth continuing?

Any prescription depends on an individual evaluation by a licensed provider. Approval is never automatic.

Who Should Not Self-Prescribe Metformin

Honestly? Nobody should. Metformin is prescription-only for good reason. Off-label use for aging needs a provider who knows your kidneys, liver, labs and goals.

A provider also weighs what you'd give up. If you're training hard, blunted exercise gains may outweigh unproven longevity benefits.

Comparing metformin with other metabolic options? Our breakdown of berberine vs metformin and MOTS-c vs metformin covers the evidence for each.

Longevity Habits With Stronger Evidence

Here's the slightly unglamorous truth. The habits with the best human data still beat any pill.

  1. Regular exercise, mixing aerobic and strength work. See our Zone 2 vs HIIT guide.
  2. Consistent, adequate sleep.
  3. A diet built on whole foods with enough protein to keep muscle.
  4. Not smoking, and limiting alcohol.
  5. Tracking biomarkers like blood sugar, lipids and blood pressure over time. Our longevity biomarkers guide lists ten worth watching.

None of these come with a boxed warning. That's worth remembering when a single drug gets marketed as the answer.

Frequently Asked Questions

Does metformin extend lifespan in humans?

Not proven. Some observational studies in people with type 2 diabetes suggest better survival on metformin, but a large Danish reanalysis did not confirm a survival advantage. No randomized trial has shown metformin extends lifespan in healthy people. The planned TAME trial is designed to test related questions in older adults.

What is the metformin longevity study?

People usually mean MILES, the Metformin in Longevity Study, or the planned TAME trial. MILES gave 14 older adults metformin and placebo for six weeks each and found gene activity changes. TAME is designed to enroll about 3,000 older adults and track age-related conditions over several years.

Does metformin interfere with exercise benefits?

Two randomized trials suggest it can. In older adults, metformin weakened gains in insulin sensitivity, VO2 max and muscle mitochondrial function after aerobic training. In the MASTERS trial, it reduced lean mass gains from strength training. Talk with a provider if exercise is central to your longevity plan.

Is metformin FDA-approved for anti-aging?

No. Metformin is FDA-approved for type 2 diabetes, not for aging or longevity. Using it to slow aging is off-label. Any prescription for that purpose would depend on an individual evaluation by a licensed provider who weighs your health history, labs and the limited evidence.

What are the side effects of metformin?

The most common side effects are stomach-related, including nausea, diarrhea and gas. Long-term use can lower vitamin B12. The FDA label carries a boxed warning for lactic acidosis, a rare but serious condition, with higher risk in people with kidney or liver problems.

Is there an alternative to metformin for longevity?

Exercise, sleep, diet and not smoking have the strongest human evidence. Some people explore berberine, NAD+ or mitochondrial peptides like MOTS-c, though evidence for each is limited and compounded peptides are not FDA-approved. A licensed provider can help you weigh options against your goals and history.

TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.

Start your private evaluation at TelosRX.

Related research

Compounded medications are compounded, not FDA-approved. Prescriptions are never automatic or guaranteed. TelosRX operates under LegitScript-certified telehealth standards as an online-first, asynchronous telehealth service.

Read more from TelosRX